Oncology Application Articles & Analysis
17 news found
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...
ByOncoVITA
Besides their allergy program, ANGANY is also working in developing other immunotherapy applications including degenerative disease and oncology for both human and veterinary indications. ...
(NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense System events at the European Conference on Interventional Oncology (ECIO) from April 24 to 27, ...
PRINCETON, N.J., MARCH 30, 2022 – Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. ...
Gauden served as Product Leader for oncology molecular imaging at GE Healthcare, with business responsibility for the product portfolio, licensing, product development and strategic marketing activities across a range of developmental PET drugs. ...
The abstract titled “The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device” analyzes data collected using both SOZO and DXA in healthy participants and cancer patients. ...
(TrueBinding), an early stage biotherapeutics development company focused on creating molecules for applications in immuno-oncology and other disease areas with unmet medical needs. ...
The latest call for proposals aims to provide funding for clinical research programs that leverage NGS in solid tumors and hematology-oncology applications. The Oncomine Clinical Research Grant awards independent clinical research proposals with up to $200,000 in reagents and general funding. Applications are reviewed for scientific merit and ...
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...
Lilli has 20 years of research and development experience in multiple fields including all areas of interest to Virometix – vaccines, infectious diseases, and oncology. She has a PhD in Molecular Biology and Genetics from the University of Zurich. Lilli joins Virometix from Redbiotec AG, where she was CSO, headed the HSV-2 Therapeutic Vaccine Program and built a pipeline ...
GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Oncology test utilization and payor coverage is accelerating, and the total NGS oncology opportunity is expected ...
"High-throughput technologies for genetic analysis are the future of molecular diagnostics," said Nikolai Kuznetsov, CEO, First Genetics. "Today we have expanded applications of NGS into reproductive medicine in Russia, and in the future, we intend to offer clinically certified solutions for other clinical applications, such as oncology testing. ...
Its unprecedented speed to results and automation is designed to accelerate a broad range of applications, including oncology, infectious disease and reproductive health, among others. ...
Program irom Jb rnarmaceuticais Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals Clovis currently planning to file an IND for FAP-targeted radiopharmaceutical therapy in 2H 2020 FAP highly expressed in multiple tumor types; Clovis to pursue broad and ...
Thermo Fisher Scientific, the world leader in serving science, will present a series of abstracts that will highlight exciting advances in clinical research with applications in immuno-oncology, tumor biology and biomarker discovery during the American Association for Cancer Research (AACR) 2018 Annual Meeting (booth #1805) in Chicago, April 14-18. ...
“This also strengthens the way we trust in our IMX313 technology, which will now be used in immuno-oncology. Its field of application is not limited to infectious diseases ...
Biopticon Corporation reaches milestone in market adoption of their innovative Tumor Management System for preclinical oncology studies. Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today announced that it had met its first milestone for customer adoption of the ...